This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Pediatric Vaccines Market To 2017- Strategic Focus On Partnering As Licensing And Co-Development Accounted For 69% Of Deal-Making Activity From 2004-2011

NEW YORK, Feb. 6, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Pediatric Vaccines Market to 2017- Strategic Focus on Partnering as Licensing and Co-Development Accounted for 69% of Deal-Making Activity from 2004-2011

http://www.reportlinker.com/p0799192/Pediatric-Vaccines-Market-to-2017--Strategic-Focus-on-Partnering-as-Licensing-and-Co-Development-Accounted-for-69%-of-Deal-Making-Activity-from-2004-2011.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication

Pediatric Vaccines Market to 2017- Strategic Focus on Partnering as Licensing and Co-Development Accounted for 69% of Deal-Making Activity from 2004-2011

Summary

GBI Research, the leading business intelligence provider, has released its latest research, "Pediatric Vaccines Market to 2017- Strategic Focus on Partnering as Licensing and Co-Development Accounted for 69% of Deal-Making Activity from 2004-2011", which provides insights into global pediatric vaccines market forecast until 2017. The report provides an in-depth analysis of six vaccines which include hepatitis A, hepatitis B, polio, rotavirus, Mumps, Measles and Rubella (MMR) and Diphtheria, Tetanus and Pertussis (DTaP). The report also examines the immunization schedules for the covered vaccines. In addition, the report also includes insights into the vaccines Research and Development (R&D) pipeline.

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts.

GBI Research analysis shows that the overall global pediatric vaccines market was valued at $14 billion in 2010. The market is expected to witness a growth at a CAGR of 11.5% for the forecast period and will reach $24.3 billion by 2017. The global market revenues are expected to increase due to the introduction of new molecules which are currently in the regulatory filing stage and those in the later stages of development. The top pharmaceutical companies in the vaccines market are – GlaxoSmithKline, Sanofi, Pfizer, Novartis AG., Merck & co. Inc and SP-MSD. Approximately 88% of the market is covered by the above six companies.

Scope

- Data and analysis on the global pediatric vaccines market

1 of 11

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 17,826.30 -279.47 -1.54%
S&P 500 2,081.18 -23.81 -1.13%
NASDAQ 4,931.8150 -75.9760 -1.52%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs